By Galen Care Partners on Thursday, 27 April 2017
Category: Galen Care Partners News

RCC Patients May Benefit from Nivolumab After Disease Progression

Nivolumab treatment beyond disease progression results in reductions in tumor burden, study finds.
Original link
Leave Comments